A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
Status:
Terminated
Trial end date:
2019-01-22
Target enrollment:
Participant gender:
Summary
This study will evaluate the pharmacodynamic (PD), safety, antitumor activity, and PK of
eFT508 in female subjects who have pathologically documented, radiographically measurable,
metastatic or locally advanced and unresectable TNBC and have received prior cancer therapy
regimen for metastatic disease, and in male and female subjects who have histologically or
cytologically confirmed advanced HCC not amenable to surgical resection and have failed
systemic therapy.